IGF-I therapy in growth disorders.

Area of Science:

• Pediatric Endocrinology
• Genetics
• Metabolic Disorders

Background:

• Growth hormone (GH) insensitivity, often due to mutations in the GH receptor (GHR) or IGF-I gene, leads to unresponsiveness to standard GH therapy.
• Insulin-like growth factor-I (IGF-I) administration has shown efficacy in treating GH-insensitive patients since the 1990s.
• Observed adverse effects of IGF-I, such as hypoglycemia and lymphoid overgrowth, are generally transient.

Purpose of the Study:

• To evaluate the efficacy and safety of IGF-I treatment in patients with GH insensitivity.
• To compare the therapeutic outcomes of IGF-I with GH treatment.
• To inform future research directions for short stature treatment.

Main Methods:

• Review of clinical trials involving IGF-I administration in patients with GH insensitivity.
• Analysis of short- and long-term efficacy data from IGF-I treatment studies.
• Assessment of adverse events associated with IGF-I therapy.

Main Results:

• IGF-I treatment demonstrated both short- and long-term efficacy in GH-insensitive patients.
• Efficacy of IGF-I was less pronounced compared to GH treatment in GH-deficient patients.
• Adverse effects including hypoglycemia and benign intracranial hypertension were noted but typically transient.

Conclusions:

• IGF-I is a viable treatment option for patients with GH insensitivity.
• Controlled clinical trials comparing GH, IGF-I, and combination therapies are essential.
• Further research is needed to optimize treatment strategies for idiopathic short stature.